Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63187-702

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63187-702). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of duloxetine hydrochloride, showing the molecular arrangement including a naphthalene group, a thiophene ring, and a methylamino group with hydrochloride.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line chart showing the percentage of patients improved plotted against percent improvement in pain from baseline. The chart compares four groups: CYM 60mg BID, CYM 60mg QD, CYM 20mg QD, and Placebo. Each group has a distinct line style and marker, illustrating trends in patient improvement across varying levels of pain reduction.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: CYM 60mg BID, CYM 60mg QD, and placebo. The graph displays decreasing percentages of patients improved as the percent improvement threshold increases from greater than 0 to 100 percent.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph comparing the percentage of patients improved on the vertical axis with percent improvement in pain from baseline (BOCF) on the horizontal axis. It shows two lines: one for placebo and one for CYM60/120 mg once daily, illustrating patient response at different levels of pain improvement.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The chart features two lines: one representing placebo and the other representing CYM60 mg once daily. The y-axis shows percentage of patients improved, and the x-axis shows percent pain improvement increments from >0 to 100. The graph visually depicts greater patient improvement with CYM60 mg once daily compared to placebo across different pain improvement percentages.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines represent placebo and CYM 60/120 mg once daily, comparing patient improvement rates at various pain improvement thresholds from >0% to 100%.*

FDA Label Image

63187-702-30 (Duloxetine 08)

Label for Duloxetine Delayed-Release Capsules 30 mg by Proficient Rx LP. The label specifies each capsule contains 33.7 mg duloxetine hydrochloride USP, equivalent to 30 mg duloxetine. The product ID is PD070230, manufactured by Laboratorios Dr. Esteve, Barcelona, Spain. The label includes dispensing instructions, storage temperature, and caution to keep medication out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.